Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;266(8):725-736.
doi: 10.1007/s00406-016-0684-7. Epub 2016 Mar 22.

The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice

Affiliations
Review

The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice

Hans-Jürgen Möller et al. Eur Arch Psychiatry Clin Neurosci. 2016 Dec.

Abstract

According to ICD-10 criteria, mixed anxiety and depressive disorder (MADD) is characterized by co-occurring, subsyndromal symptoms of anxiety and depression, severe enough to justify a psychiatric diagnosis, but neither of which are clearly predominant. MADD appears to be very common, particularly in primary care, although prevalence estimates vary, often depending on the diagnostic criteria applied. It has been associated with similarly pronounced distress, impairment of daily living skills, and reduced health-related quality of life as fully syndromal depression and anxiety. Although about half of the patients affected remit within a year, non-remitting patients are at a high risk of transition to a fully syndromal psychiatric disorder. The validity and clinical usefulness of MADD as a diagnostic category are under debate. It has not been included in the recently released DSM-5 since the proposed diagnostic criteria turned out to be not sufficiently reliable. Moreover, reviewers have disputed the justification of MADD based on divergent results regarding its prevalence and course, diagnostic stability over time, and nosological inconsistencies between subthreshold and threshold presentations of anxiety and depressive disorders. We review the evidence in favor and against MADD and argue that it should be included into classification systems as a diagnostic category because it may enable patients to gain access to appropriate treatment early. This may help to reduce patients' distress, prevent exacerbation to a more serious psychiatric disorder, and ultimately reduce the societal costs of this very common condition.

Keywords: Classification; Mixed anxiety and depression; Psychiatric disorder; Subthreshold anxiety; Subthreshold depression.

PubMed Disclaimer

Conflict of interest statement

Prof. Dr. Hans-Jürgen Möller has received grant/research support, consulting fees, and honoraria within the last years from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, MSD, Novartis, Organon, Otsuka, Pfizer, Schwabe, Sepracor, Servier, and Wyeth. Prof. Dr. Bandelow has received consultant’s fees from Lundbeck, Otsuka, and Pfizer and honoraria for lecturing at continuing medical education events from Glaxo, Janssen, Lundbeck, Meiji-Seika, Pfizer, and Servier. Prof. Dr. Hans-Peter Volz has served as a consultant or on advisory boards for AstraZeneca, Lundbeck, Pfizer, Schwabe, Otsuka, Merz, Lilly, Janssen, Neuraxpharm, Steigerwald and has served on speakers’ bureaus for AstraZeneca, Eli Lilly, Lundbeck, Schwabe, Janssen, Merz, Steigerwald, Otsuka, Neuraxpharm, Steigerwald, Bristol-Myers Squibb, Tromssdorff. Prof. Dr. Utako Birgit Barnikol has no disclosures and no conflicts of interests to declare. Prof. Dr. Erich Seifritz’s work has been funded by the University of Zürich and the Swiss National Science Foundation. He has received compensation as a member of the scientific advisory boards of Lundbeck, Otsuka, Janssen, Eli Lilly, Schwabe, and Takeda. He gave scientific talks in symposia financed by Eli Lilly, Astra Zeneca, Lundbeck, Schwabe, Opopharma, and Janssen. Prof. Dr. Siegfried Kasper has received grant/research support from Eli Lilly, GlaxoSmithKline, Lundbeck, Pfizer, and Servier; he has served as a consultant or on advisory boards for AstraZeneca, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Novartis, Pfizer, Schwabe, and Servier; he has served on speakers’ bureaus for Angelini, AOP Orphan Pharmaceuticals AG, AstraZeneca, Eli Lilly, Janssen, Krka Pharma, Lundbeck, Neuraxpharm, Pfizer, Pierre Fabre, Schwabe, Servier.

Similar articles

Cited by

References

    1. Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety. 1996;4(4):160–168. doi: 10.1002/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J. - DOI - PubMed
    1. Angst J, Merikangas K (1997) The depressive spectrum: diagnostic classification and course. J Affect Disord 45 (1–2):31–39; discussion 39-40 - PubMed
    1. Heun R, Papassotiropoulos A, Ptok U. Subthreshold depressive and anxiety disorders in the elderly. Eur Psychiatry. 2000;15(3):173–182. doi: 10.1016/S0924-9338(00)00228-5. - DOI - PubMed
    1. Tiller JWG. Depression and anxiety. MJA Open. 2012;1(Suppl 4):28–32.
    1. World Health Organization . International statistical classification of diseases and related health problems, tenth revision (ICD-10) Geneva: World Health Organization; 1992.

MeSH terms